Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study
| Autor: | Thomas F. Rocereto, Steven E Waggoner, John A. Blessing, Jonathan S. Berek, Judith K. Wolf, Paula M. Fracasso |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
medicine.medical_specialty Organoplatinum Compounds Nausea medicine.medical_treatment Uterine Cervical Neoplasms Phases of clinical research Antineoplastic Agents Gastroenterology chemistry.chemical_compound Internal medicine medicine Humans Cisplatin Chemotherapy business.industry Obstetrics and Gynecology Middle Aged Chemotherapy regimen Carboplatin Surgery Oxaliplatin Oncology chemistry Epidermoid carcinoma Carcinoma Squamous Cell Female medicine.symptom business medicine.drug |
| Zdroj: | Gynecologic Oncology. 90:177-180 |
| ISSN: | 0090-8258 |
| DOI: | 10.1016/s0090-8258(03)00253-1 |
| Popis: | Objective A phase II study was conducted to determine the efficacy of oxaliplatin therapy in patients with previously treated squamous cell carcinoma of the cervix. Methods Eligible patients were to have measurable disease and not more than one prior chemotherapy regimen that could include carboplatin or cisplatin but not oxaliplatin. Oxaliplatin 130 mg/m 2 was administered intravenously over 2 h. This treatment was repeated every 21 days until progression of disease or adverse effects prohibited further therapy. Results Twenty-eight patients were entered onto this study, of whom 24 were evaluable for toxicity and 22 were evaluable for response; 23/24 evaluable patients had had prior platinum. There were two (8.3%) responses. One patient achieved a complete response which lasted 2.2 months, and a second patient attained a partial response which lasted 3.2 months. Nine (37.5%) patients had stable disease with a median duration of 7.6+ (3.1–21.2) months. The most frequently reported drug-related toxicities consisted of anemia, nausea and vomiting, and neurotoxicity. Three (12.5%) patients had a grade 3 allergic response that was infusion-related and was largely resolved by increasing infusion time. Conclusions Oxaliplatin has limited activity in patients with persistent or recurrent squamous cell carcinoma of the cervix at the dose and schedule tested. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect